# P. Anton van der Merwe
**Philip Anton van der Merwe** is an immunologist who trained in medicine and completed a PhD at the [University of Cape Town](https://www.edgepedia.org/university-of-cape-town) in South Africa, and is Professor of Molecular Immunology at the [University of Oxford](https://www.edgepedia.org/university-of-oxford), known for the kinetic-segregation model of [T-cell receptor](https://www.edgepedia.org/t-cell-receptor) triggering and for work on how white blood cells recognize infected or cancerous cells.[1](https://www.ox.ac.uk/news-and-events/find-an-expert/professor-anton-van-der-merwe) • [2](https://hstalks.com/expert/3648/prof-anton-van-der-merwe/) Recent advances in this area underpin cancer treatments such as checkpoint inhibitors and CAR T cells.[1](https://www.ox.ac.uk/news-and-events/find-an-expert/professor-anton-van-der-merwe) He became jointly head of the Molecular Immunology Group at the Sir William Dunn School of Pathology, which aims to develop a quantitative understanding of how signals from many surface receptors are integrated into a T cell response decision.[3](https://mig.site.ox.ac.uk/home)
| Key facts | |
|---|---|
| Full name | Philip Anton van der Merwe[4](https://orcid.org/0000-0001-9902-6590) |
| Position | Professor of Molecular Immunology, University of Oxford[1](https://www.ox.ac.uk/news-and-events/find-an-expert/professor-anton-van-der-merwe) |
| Field | Immunology: leukocyte receptor signaling and T-cell antigen recognition[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) |
| Training | MBChB (1981–1985), BSc Hons Medical Biochemistry (1987), PhD Chemical Pathology (1988–1990), University of Cape Town[4](https://orcid.org/0000-0001-9902-6590) |
| Signature work | 2005 Nature paper showing TCR triggering depends on the dimensions of its peptide-MHC ligand[6](https://www.nature.com/articles/nature03843) |
| Known for | The kinetic-segregation model of T-cell receptor triggering, proposed in 1996[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) |
| Company | Co-founder of MatchBio, launched January 2024 with £4.5M from Oxford Science Enterprises[7](https://www.immunology.ox.ac.uk/news/new-oxford-immunology-spin-out-company-working-to-improve-immunotherapy-matchbio) |
## Education and early career
Van der Merwe qualified in medicine at the University of Cape Town, completing an MBChB between 1981 and 1985, followed by a BSc honors degree in Medical Biochemistry in 1987 and a PhD in Chemical Pathology between 1988 and 1990.[4](https://orcid.org/0000-0001-9902-6590) After his PhD he joined the MRC Cellular Immunology Unit, located within the Sir William Dunn School of Pathology at Oxford, to work on [T cell](https://www.edgepedia.org/t-cell) surface molecules; according to his HSTalks profile, he worked there with Professors Alan Williams and Neil Barclay.[8](https://www.matchbiotx.com/our-founders) • [2](https://hstalks.com/expert/3648/prof-anton-van-der-merwe/) • [1](https://www.ox.ac.uk/news-and-events/find-an-expert/professor-anton-van-der-merwe)
## Career at Oxford
He is Professor of Molecular Immunology at the University of Oxford.[1](https://www.ox.ac.uk/news-and-events/find-an-expert/professor-anton-van-der-merwe) His laboratory at the Sir William Dunn School of Pathology studies the mechanisms by which leukocytes, such as T cells, use cell surface receptors, such as the T cell receptor (TCR), to recognize infected or otherwise [abnormal cells](https://www.edgepedia.org/abnormal-cell).[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) The Molecular Immunology Group, which he heads jointly with a colleague, applies quantitative analysis of receptor signaling to improve immune therapies.[3](https://mig.site.ox.ac.uk/home) In addition to research he became Director of Graduate Studies and teaches immunology to medical and biomedical science students.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/)
## Representative work
His 2005 Nature paper showed that increasing the dimensions of the TCR–peptide-MHC interaction by elongating the pMHC (peptide bound to an MHC protein, shown to T cells) ectodomain (the outward-facing part of a cell-surface protein) greatly reduces TCR triggering without affecting TCR–pMHC ligation, supporting a role for size-based segregation of cell-surface molecules in TCR triggering.[6](https://www.nature.com/articles/nature03843) Interfaces between T cells and antigen-presenting cells expressing elongated pMHC showed increased intermembrane separation and less depletion of CD45, the phosphatase central to the model.[6](https://www.nature.com/articles/nature03843) The paper is published at [doi:10.1038/nature03843](https://doi.org/10.1038/nature03843).
A 2002 Science Perspective on the immunological synapse discussed findings demonstrating that T cell receptor signaling takes place well before formation of the synapse, suggesting that this dynamic structure may have functions beyond enhancing and sustaining TCR signaling.[9](https://doi.org/10.1126/science.1069896) His 2006 Nature Immunology review, [The kinetic-segregation model: TCR triggering and beyond](https://doi.org/10.1038/ni1369), described the first direct support for the mechanism proposed ten years earlier and indications that it may also apply to nonclonotypic receptors.[10](https://doi.org/10.1038/ni1369)
## The kinetic-segregation model
The kinetic-segregation (KS) model was originally proposed in 1996.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) In this mechanism, CD45, which dephosphorylates the TCR and molecules recruited to it, is passively excluded from close contact zones because of its large ectodomain; the local loss of phosphatase allows the kinase Lck to phosphorylate the TCR, triggering signaling.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) The process is nucleated by small proteins such as CD2, which form tight contacts and drive local size-dependent exclusion of large proteins such as CD45 from the close-contact zone.[10](https://doi.org/10.1038/ni1369) Evidence has accumulated from studies including work in 2005, 2013, and 2024 from his laboratory.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/)
The model extends beyond the TCR: CD28, [NKG2D](https://www.edgepedia.org/nkg2d), Dectin-1, FcγR, and FcεR have all been reported to signal through kinetic segregation, and a 2024 generic ligand study provided evidence that four further receptor families use it.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) Synthetic chimeric antigen receptors based on the TCR, which are transforming cancer treatment, also use the mechanism.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/)
## MatchBio and current research
In January 2024 he co-founded MatchBio, a spin-out from the Dunn School laboratories, launched with a £4.5M investment from Oxford Science Enterprises.[7](https://www.immunology.ox.ac.uk/news/new-oxford-immunology-spin-out-company-working-to-improve-immunotherapy-matchbio) • [11](https://www.path.ox.ac.uk/news-article/new-advances-towards-optimising-the-antigen-sensitivity-of-car-t-cells/) According to the University of Oxford's announcement of the spin-out, MatchBio engineers CAR-T cells with better sensitivity and specificity so that cancer cells cannot escape therapy by lowering their antigens, and improved CARs may also treat intractable infections and autoimmune disease.[7](https://www.immunology.ox.ac.uk/news/new-oxford-immunology-spin-out-company-working-to-improve-immunotherapy-matchbio) The underlying approaches were developed in the Oxford labs with funding from the [Wellcome Trust](https://www.edgepedia.org/wellcome-trust), the [Medical Research Council](https://www.edgepedia.org/medical-research-council), and a Guy Newton Translational Grant.[7](https://www.immunology.ox.ac.uk/news/new-oxford-immunology-spin-out-company-working-to-improve-immunotherapy-matchbio)
In current research, his group investigates how to measure and optimize the sensitivity and specificity of synthetic immunoreceptors such as CARs, and how TCR/ligand binding properties and mechanical forces influence T cell activation.[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) A 2021 eLife study from the group found that primary human T cells can respond to pMHC with affinities as low as KD ∼ 1 mM, and provided estimates of the kinetic-proofreading time delay (2.8 s) and number of biochemical steps (2.67) consistent with the sensitivity of antigen recognition.[12](https://ora.ox.ac.uk/objects/uuid:f6f6f327-aadf-445d-896b-0040d4f1f61e/files/rd217qp791)
## Recent developments
The laboratory has remained active. Its 2024 output includes a Cell Reports paper on ligand-induced segregation from large cell-surface phosphatases in γδ TCR triggering (43(9):114761) and a Communications Biology paper, "Ligand requirements for immunoreceptor triggering" (7(1):1138).[5](https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/) In November 2025, an EMBO Journal article reported that the murine T-cell receptor OT-I exhibits imperfect discrimination between foreign and self-antigens.[4](https://orcid.org/0000-0001-9902-6590) In January 2026, a Nature Biomedical Engineering paper described the generation of T cells with reduced off-target cross-reactivities by engineering co-signaling receptors.[4](https://orcid.org/0000-0001-9902-6590)
## References
1. Professor Anton Van der Merwe, University of Oxford. https://www.ox.ac.uk/news-and-events/find-an-expert/professor-anton-van-der-merwe
2. Prof. Anton van der Merwe, HSTalks. https://hstalks.com/expert/3648/prof-anton-van-der-merwe/
3. Molecular Immunology Group, University of Oxford. https://mig.site.ox.ac.uk/home
4. Philip Anton van der Merwe, ORCID 0000-0001-9902-6590. https://orcid.org/0000-0001-9902-6590
5. Recognition of Abnormal Cells by Leukocyte Receptors, Sir William Dunn School of Pathology. https://www.path.ox.ac.uk/research-group/anton-van-der-merwe/
6. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand, Nature (2005). https://www.nature.com/articles/nature03843
7. New Oxford Immunology Spin-out Company working to Improve Immunotherapy: MatchBio. https://www.immunology.ox.ac.uk/news/new-oxford-immunology-spin-out-company-working-to-improve-immunotherapy-matchbio
8. Our Founders, MatchBio. https://www.matchbiotx.com/our-founders
9. The Immunological Synapse, a Multitasking System, Science (2002). https://doi.org/10.1126/science.1069896
10. The kinetic-segregation model: TCR triggering and beyond, Nature Immunology (2006). https://doi.org/10.1038/ni1369
11. New advances towards optimising the antigen sensitivity of CAR-T cells, Dunn School. https://www.path.ox.ac.uk/news-article/new-advances-towards-optimising-the-antigen-sensitivity-of-car-t-cells/
12. The discriminatory power of the T cell receptor, eLife (2021). https://ora.ox.ac.uk/objects/uuid:f6f6f327-aadf-445d-896b-0040d4f1f61e/files/rd217qp791
---
*Topic: Encyclopedia › Life and health › Life and health scientists › Life scientists › Researchers in immunology, microbiology, and virology › T cell development and signaling › T cell receptor signaling*
*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026 · Edited: Sep 25, 2026; Oct 11, 2026; Oct 15, 2026 · Last review: Sep 25, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license